Figure 2From: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study Effect of hypertension (a) and proteinuria (b) on time to progression. Back to article page